From bench to bedside – A mission for a healthy life
From bench to bedside – A mission for a healthy life
The DRFZ investigates the long‐term outcomes of rheumatic diseases, including the impact of current treatment options, in order to inform clinical decision making, identify unmet needs and improve health care. Biomedical research identifies the cells initiating and those driving rheumatic diseases, and the underlying molecular mechanisms. Our aim is the development of improved, personalised, at best curative therapies for patients with rheumatic diseases, and their rapid translation into clinical practice.
News
Eicke Latz – Highly Cited Researcher at the DRFZ
Biomarker identified that predicts therapeutic success in chronic inflammatory bowel disease
NAKO study: more frequent depression, but no differences in cognitive tests in rheumatic disease
Preisverleihung der Stiftung Wolfgang Schulze 18.11.24 im Abgeordnetenhaus
Science at DRFZ
Emilia Schneider Revueltas: Surface CD69-negative bone marrow-resident human memory T cells
Jelizaveta Fadejeva: The role of soluble interleukin-33 receptor sST2 in type 2 immunity
Pendar Alirezazadeh: Deep Learning-based Cell Segmentation in Immunofluorescence Imaging Using DeepLabV3+: A Precision Approach
Florian Milatz: Konzept zur Frühdiagnostik einer juvenilen idiopathischen Arthritis
Mediathek
News | 21.November 2022
Mir-Farzin Mashreghi
...... is the new head of the Systems Rheumatology Research Department
News | 10. March 2022
Anja Strangfeld
... is the head of the Programme Area Epidemiology at the DRFZ
News | 02. November 2022
Carsten Watzl
... has been Chairman of the Scientific Advisory Board of the DRFZ since September 2022